Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT01339091 · View on ClinicalTrials.gov ↗
Study Summary
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection.
Conditions Studied
Interventions
- DRUG Dalbavancin
- DRUG Vancomycin / Linezolid
Study Locations (20)
California
- Durata Study Site — Anaheim
- Durata Study Site — Azusa
- Durata Study Site — Bellflower
- Durata Study Site — Buena Park
- Durata Study Site — Carmel
- Durata Study Site — Chula Vista
- Durata Study Site — Covina
- Durata Study Site — Fountain Valley
- Durata Study Site — La Mesa
- Durata Study Site — Long Beach
- Durata Study Site — Los Alamitos
- Durata Study Site — Los Angeles
- Durata Study Site — Oceanside
- Durata Study Site — Palm Desert
- Durata Study Site — Pasadena
- Durata Study Site — Sacramento
- Durata Study Site — San Diego
- Durata Study Site — Santa Ana
- Durata Study Site — Sylmar
- Durata Study Site — Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339091
The ClinicalTrials.gov registry entry for NCT01339091 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durata Therapeutics Inc., an affiliate of Allergan, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Surgical Site Infection appearing as the primary indexed condition, and to 2 interventions — of which Dalbavancin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01339091 reports 20 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01339091 about?
NCT01339091 is a clinical study titled "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections". The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infect...
What is the current status of trial NCT01339091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 573 participants. The study started on 2011-03. Estimated completion is 2012-11.
What conditions does trial NCT01339091 study?
This clinical trial studies the following conditions: Surgical Site Infection, Abscess, Cellulitis, Wound Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01339091?
The interventions under investigation include: Dalbavancin (DRUG), Vancomycin / Linezolid (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01339091?
This trial is sponsored by Durata Therapeutics Inc., an affiliate of Allergan, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01339091 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.